Kidney Cancer Coverage From Every Angle
Advertisement
Advertisement

Toni K. Choueiri, MD, and Michael D. Staehler, MD, PhD, on RCC: Results From the SWITCH-II and SURTIME Trials

Posted: Wednesday, October 4, 2017

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Michael D. Staehler, MD, PhD, of the University of Munich, discuss study findings on sorafenib-pazopanib vs pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (mRCC); and immediate vs deferred cytoreductive nephrectomy in patients with synchronous mRCC receiving sunitinib.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.